Risk Stratification

Combination Testing With ThyGeNEXT and ThyraMIR Provides Accurate Reclassification1

ThyGeNEXT + ThyraMIR Combination Testing Performance1

High NPV

  • Significant decrease in unnecessary surgeries
  • 85% reduction relative to cytology alone (P<0.01)

Testing helps to risk-stratify the need for or extent of surgery needed

ATA and NCCN Guidelines support testing for nodules with a B-III or B-IV cytology diagnosis

50 %
Sensitivity
50 %
NPV
50 %
Specificity
40 %
PPV

Markers

Strategically Designed Panel for the Optimal Management of Thyroid Nodules

ThyGeNEXT® NGS PanelThyraMIR® miRNA classifier
DNA mutation panelRNA panel (# fusions)
ALKALK (2)miR-29b-1-5p
BRAFBRAF (2)miR-31-5p
GNASNTRK (8)miR-138-1-3p
HRASPPARg (6)miR-139-5p
KRASRET (14)miR-146b-5p
NRASTHADA (5)miR-155
PIK3CAmRNA controls:
NKX2-1, PAX8, TBP, USP33
miR-204-5p
PTENmiR-222-3p
RETmiR-375
TERTmiR-551b-3p

Newly added TERT and ALK mutations can reliably help to predict aggressive biological features of thyroid cancer, including:

  • Large tumor size
  • Higher patient mortality
  • Likelihood of lymph node metastasis
  • Higher rate of recurrence post-treatment
  • Higher clinical stage at time of cancer detection
  • Likelihood of cancer spreading beyond the thyroid
  • Increased risk for tumor vascular invasion
  • Potential for treatment failure

Long-Term Evidence

Impact of BRAF V600E or TERT C288T Alone or Their Coexistence on Disease-free Survival of Patients With PTC2

Coexisting BRAF V600E and TERT C228T mutations form a novel genetic background that defines PTC with the potentially worst clinicopathologic outcomes, providing unique prognostic and therapeutic implications.

References

  1. Labourier, et al, Journal Clinical Endocrinology Metabolism 100: 2743, 2015
  2. Xing M et al., BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence, Journal of Clinical Oncology 2014

Interpace Diagnostics and the molecule logo are registered trademarks of Interpace Diagnostics, LLC.
©2018 Interpace Diagnostics, LLC. All rights reserved.

  • 844-905-9655
  • info@interpacedx.com
Scroll to Top